Annual EBITDA
-$104.45 M
+$9.36 M+8.22%
31 December 2023
Summary:
Foghorn Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$104.45 million, with the most recent change of +$9.36 million (+8.22%) on 31 December 2023. During the last 3 years, it has fallen by -$37.96 million (-57.09%). FHTX annual EBITDA is now -308.23% below its all-time high of -$25.59 million, reached on 31 December 2018.FHTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$23.12 M
+$324.00 K+1.38%
30 September 2024
Summary:
Foghorn Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$23.12 million, with the most recent change of +$324.00 thousand (+1.38%) on 30 September 2024. Over the past year, it has dropped by -$6.90 million (-42.56%). FHTX quarterly EBITDA is now -80.49% below its all-time high of -$12.81 million, reached on 30 September 2019.FHTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$98.53 M
-$6.90 M-7.53%
30 September 2024
Summary:
Foghorn Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$98.53 million, with the most recent change of -$6.90 million (-7.53%) on 30 September 2024. Over the past year, it has increased by +$12.36 million (+11.15%). FHTX TTM EBITDA is now -669.20% below its all-time high of -$12.81 million, reached on 30 September 2019.FHTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
FHTX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +8.2% | -42.6% | +11.2% |
| 3 y3 years | -57.1% | +6.5% | -11.8% |
| 5 y5 years | -308.2% | -80.5% | -669.2% |
FHTX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -57.1% | +8.2% | -42.6% | +28.8% | -11.8% | +19.3% |
| 5 y | 5 years | -308.2% | +8.2% | -80.5% | +28.8% | -669.2% | +19.3% |
| alltime | all time | -308.2% | +8.2% | -80.5% | +28.8% | -669.2% | +19.3% |
Foghorn Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$23.12 M(-1.4%) | -$98.53 M(+7.5%) |
| June 2024 | - | -$23.44 M(-14.3%) | -$91.63 M(-7.8%) |
| Mar 2024 | - | -$27.36 M(+11.2%) | -$99.36 M(-4.9%) |
| Dec 2023 | -$104.45 M(-8.2%) | -$24.61 M(+51.7%) | -$104.45 M(-5.8%) |
| Sept 2023 | - | -$16.22 M(-48.0%) | -$110.89 M(-9.2%) |
| June 2023 | - | -$31.17 M(-4.0%) | -$122.09 M(+2.4%) |
| Mar 2023 | - | -$32.46 M(+4.6%) | -$119.28 M(+4.8%) |
| Dec 2022 | -$113.82 M(+18.3%) | -$31.04 M(+13.2%) | -$113.82 M(+2.8%) |
| Sept 2022 | - | -$27.42 M(-3.4%) | -$110.69 M(+2.5%) |
| June 2022 | - | -$28.37 M(+5.1%) | -$107.99 M(+6.4%) |
| Mar 2022 | - | -$26.99 M(-3.3%) | -$101.45 M(+5.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$96.19 M(+44.7%) | -$27.91 M(+12.9%) | -$96.19 M(+9.1%) |
| Sept 2021 | - | -$24.72 M(+13.2%) | -$88.15 M(+8.4%) |
| June 2021 | - | -$21.83 M(+0.5%) | -$81.34 M(+8.8%) |
| Mar 2021 | - | -$21.73 M(+9.3%) | -$74.78 M(+12.5%) |
| Dec 2020 | -$66.49 M(+33.3%) | -$19.87 M(+11.0%) | -$66.49 M(+8.1%) |
| Sept 2020 | - | -$17.91 M(+17.3%) | -$61.50 M(+9.0%) |
| June 2020 | - | -$15.27 M(+13.6%) | -$56.40 M(+37.1%) |
| Mar 2020 | - | -$13.44 M(-9.7%) | -$41.13 M(+48.5%) |
| Dec 2019 | -$49.90 M(+95.0%) | -$14.88 M(+16.2%) | -$27.69 M(+116.2%) |
| Sept 2019 | - | -$12.81 M | -$12.81 M |
| Dec 2018 | -$25.59 M | - | - |
FAQ
- What is Foghorn Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Foghorn Therapeutics?
- What is Foghorn Therapeutics annual EBITDA year-on-year change?
- What is Foghorn Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Foghorn Therapeutics?
- What is Foghorn Therapeutics quarterly EBITDA year-on-year change?
- What is Foghorn Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Foghorn Therapeutics?
- What is Foghorn Therapeutics TTM EBITDA year-on-year change?
What is Foghorn Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of FHTX is -$104.45 M
What is the all time high annual EBITDA for Foghorn Therapeutics?
Foghorn Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$25.59 M
What is Foghorn Therapeutics annual EBITDA year-on-year change?
Over the past year, FHTX annual earnings before interest, taxes, depreciation & amortization has changed by +$9.36 M (+8.22%)
What is Foghorn Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of FHTX is -$23.12 M
What is the all time high quarterly EBITDA for Foghorn Therapeutics?
Foghorn Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$12.81 M
What is Foghorn Therapeutics quarterly EBITDA year-on-year change?
Over the past year, FHTX quarterly earnings before interest, taxes, depreciation & amortization has changed by -$6.90 M (-42.56%)
What is Foghorn Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of FHTX is -$98.53 M
What is the all time high TTM EBITDA for Foghorn Therapeutics?
Foghorn Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$12.81 M
What is Foghorn Therapeutics TTM EBITDA year-on-year change?
Over the past year, FHTX TTM earnings before interest, taxes, depreciation & amortization has changed by +$12.36 M (+11.15%)